Statistical methodology of phase III cancer clinical trials: Advances and future perspectives

European Journal of Cancer

Volumn 38, Issue SUPPL. 4, 2002, Pages 162-168

  Sylvester, R ^a   Van Glabbeke, M ^a   Collette, L ^a   Suciu, S ^a   Baron, B ^a   Legrand, C ^a   Gorlia, T ^a   Collins, G ^a   Coens, C ^a   Declerck, L ^a   Therasse, P ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

Analysis; Clinical trial; Design; Endpoints; Meta analysis; Phase III; Randomisation; Sample size; Statistics

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; CLINICAL RESEARCH; CLINICAL TRIAL; HEALTH ECONOMICS; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; METHODOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; REVIEW; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036179295     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00442-7     Document Type: Review

References (43)

1. A comparative study of two regimens of combination chemotherapy in acute leukemia
2. Note for guidance III/3630/92-EN, biostatistical methodology in clinical trials in applications for marketing authorizations for medicinal products
3. Phase I clinical trial design in cancer drug development
4. New guidelines to evaluate the response to treatment in solid tumors
5. Absence of evidence is not evidence of absence
6. Proving the null hypothesis in clinical trials
7. Streptomycin treatment of pulmonary tuberculosis
8. Non-randomized controls in cancer clinical trials
9. Randomized clinical trials: Perspectives on some recent ideas
10. Randomized clinical trials versus historical control studies
11. A new design for randomized clinical trials
12. Randomised consent designs in cancer clinical trials
13. Practical experience of randomization in cancer trials: An international survey
14. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
15. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial
16. The European organization for research and treatment of cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology
17. Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a national institutes of health workshop
18. Nonparametric estimation from incomplete observations
19. Evaluation of survival data and two new rank order statistics arising in its consideration
20. Regression models and life tables
21. Improving the quality of reporting of randomized controlled trials: The CONSORT Statement
22. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials
23. Statistical aspects of prognostic factor studies in oncology
24. Proportional hazards model with random effects
25. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials
26. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
27. Monitoring of clinical trials: Issues and recommendations
28. Role of independent data-monitoring committees in randomized clinical trials sponsored by the national cancer institute
29. Longitudinal data analysis (repeated measures) in clinical trials
30. Identifying the types of missingness in quality of life data from clinical trials
31. The role of meta-analyses in assessing cancer treatments
32. Hospital and physician volume or specialization and outcomes in cancer treatment: Importance in quality of cancer care
33. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents